Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 92

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 92
---
 involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:

| • |     | the scope of rights granted under the license agreement and other interpretation-related issues; |

| • |     | our financial or other obligations under the license agreement; |

| • |     | whether and the extent to which our technology and processes infringe on intellectual property rights of the 
 licensor that are not subject to the licensing agreement;                                                    |

| • |     | our right to sublicense intellectual property rights to third parties under collaborative development 
 relationships;                                                                                        |

| • |     | our diligence obligations with respect to the use of the licensed technology in relation to our development and 
 commercialization of our product candidates, and what activities satisfy those diligence obligations; and       |

| • |     | the ownership of inventions and know-how resulting from the joint                  
 creation or use of intellectual property by our licensors and us and our partners. |

If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. 56

If we are unable to maintain patent protection for ZTlido, GLOPERBA, ELYXYB and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to ZTlido, GLOPERBA, ELYXYB and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection